UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Industry relevant microfluidic platforms for mineral leaching experiments

Frontiers in chemical engineering, 2024-09, Vol.6

2024

Volltextzugriff (PDF)

Rapid Fabrication of Superhydrophobic Virtual Walls for Microfluidic Gas Extraction and Sensing

Micromachines (Basel), 2021-05, Vol.12 (5), p.514

2021

Volltextzugriff (PDF)

Clofarabine in the treatment of newly diagnosed acute myeloid leukemia in older adults

The Annals of pharmacotherapy, 2012-01, Vol.46 (1), p.89-96

2012

Volltextzugriff (PDF)

P688: ASC2ESCALATE: A US PHASE 2, OPEN‐LABEL, SINGLE‐ARM, DOSE‐ESCALATION STUDY OF ASCIMINIB MONOTHERAPY IN 2ND‐LINE (2L) TREATMENT OF PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML‐CP)

HemaSphere, 2023-08, Vol.7 (S3), p.e8144284-n/a

2023

Volltextzugriff (PDF)

Electrochemical behavior of oxazoline‐based plasma polymers for biosensing applications

Plasma processes and polymers, 2023-08, Vol.20 (8), p.n/a

2023

Volltextzugriff (PDF)

Pilot-scale microfluidic solvent extraction of high-value metals

Minerals engineering, 2022-05, Vol.182, p.107536, Article 107536

2022

Volltextzugriff (PDF)

Incremental Healthcare Resource Utilization and Costs Associated with Non-Optimal Treatment in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Tyrosine Kinase Inhibitors (TKI) in Early Lines of Therapy in the United States (US)

Blood, 2023-11, Vol.142 (Supplement 1), p.5098-5098

2023

Volltextzugriff (PDF)

Treatment Patterns and Modifications of Tyrosine Kinase Inhibitors (TKI) Therapy in Early Lines in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Real-World Analysis from a Large Commercial Claims Database in the United States (US)

Blood, 2023-11, Vol.142 (Supplement 1), p.5190-5190

2023

Volltextzugriff (PDF)

Outside Front Cover: Plasma Process. Polym. 8/2023

Plasma processes and polymers, 2023-08, Vol.20 (8), p.n/a

2023

Volltextzugriff (PDF)

Facile and green fabrication of efficient Au nanoparticles catalysts using plant extract via a mesoporous silica-assisted strategy

Colloids and surfaces. A, Physicochemical and engineering aspects, 2021-07, Vol.621, p.126580, Article 126580

2021

Volltextzugriff (PDF)

Treatment of Acute Promyelocytic Leukemia During Pregnancy

Pharmacotherapy, 2009-06, Vol.29 (6), p.709-724

2009

Volltextzugriff (PDF)

HSR24-147: Non-Optimal Treatment in Early-Line Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated With Tyrosine Kinase Inhibitors (TKI): A Claims Data Analysis

Journal of the National Comprehensive Cancer Network, 2024-04, Vol.22 (2.5)

2024

Volltextzugriff (PDF)

HSR24-139: Patient-Reported Outcome Measures Used in Patients With Chronic Phase-Chronic Myeloid Leukemia: A Systematic Review of the Literature

Journal of the National Comprehensive Cancer Network, 2024-04, Vol.22 (2.5)

2024

Volltextzugriff (PDF)

CML-205 Non-Optimal Treatment in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated With Tyrosine Kinase Inhibitors (TKI) in the United States: A Claims Data Analysis

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S365-S366

2024

Volltextzugriff (PDF)

Non-Optimal Treatment in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated With Tyrosine Kinase Inhibitors (TKI) in the United States: A Claims Data Analysis

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S185-S185

2024

Volltextzugriff (PDF)

ASC2ESCALATE: A US Phase 2, Open-Label, Single-Arm, Dose-Escalation Study of Asciminib (ASC) Monotherapy in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) As Second-Line (2L) and First-Line (1L) Treatment

Blood, 2023-11, Vol.142 (Supplement 1), p.6389-6389

2023

Volltextzugriff (PDF)

Solid organ transplant patients: are there opportunities for antimicrobial stewardship?

Clinical transplantation, 2016-06, Vol.30 (6), p.659-668

2016

Volltextzugriff (PDF)

ASC2ESCALATE: A US phase 2, single-arm, dose-escalation study of asciminib monotherapy in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with 1 prior tyrosine kinase inhibitor (TKI)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS7082-TPS7082

2023

Volltextzugriff (PDF)

CML-068 Quantifying the Financial Impact of Treatment Intolerance in Chronic Myeloid Leukemia on Oncology Clinical Practices: A Mixed-Methods Study

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S362-S363

2024

Volltextzugriff (PDF)

Quantifying the Financial Impact of Treatment Intolerance in Chronic Myeloid Leukemia on Oncology Clinical Practices: A Mixed-Methods Study

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S185-S185

2024

Volltextzugriff (PDF)

CML-619 Adverse Events (AEs) Among Patients With Chronic Myeloid Leukemia (CML) Receiving Tyrosine Kinase Inhibitors and Subsequent Treatment Adjustment: A Large US Commercial Claims Database Analysis

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S377-S378

2024

Volltextzugriff (PDF)

Adverse Events (AEs) Among Patients With Chronic Myeloid Leukemia (CML) Receiving Tyrosine Kinase Inhibitors and Subsequent Treatment Adjustment: A Large US Commercial Claims Database Analysis

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S189-S189

2024

Volltextzugriff (PDF)

Continuous monitoring of EDTA extractable iron from mineral slurries using a microfluidic chip

Canadian journal of chemical engineering, 2023-02, Vol.101 (2), p.944-952

2023

Volltextzugriff (PDF)

The ever-evolving landscape of candidaemia in patients with acute leukaemia: non-susceptibility to caspofungin and multidrug resistance are associated with increased mortality

Journal of antimicrobial chemotherapy, 2015-08, Vol.70 (8), p.2362-2368

2015

Volltextzugriff (PDF)

POSTER: CML-573 ASC2ESCALATE: A US, Phase II Open-Label, Single-Arm, Dose-Escalation Study of Asciminib Monotherapy in Second-Line (2L) and First-Line (1L) Treatment of Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S178-S178

2023

Volltextzugriff (PDF)

1 – 25 von 249

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(199)
Mit Volltextzugriff
(215)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(136)
Life Sciences & Biomedicine
(91)
Humans
(61)
Animals
(29)
Physical Sciences
(29)
Male
(27)
Technology
(27)
Chemistry
(26)
Female
(26)
Biochemistry & Molecular Biology
(17)
Cell Biology
(16)
Computer Science
(15)
Mice
(15)
Middle Aged
(14)
Adult
(13)
Aged
(13)
Biological And Medical Sciences
(11)
Computer Science, Information Systems
(11)
Medical Sciences
(11)
Engineering
(10)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(12)

Menü

Weitere Dienste

Einstellungen

Industry relevant microfluidic platforms for mineral leaching experiments

Rapid Fabrication of Superhydrophobic Virtual Walls for Microfluidic Gas Extraction and Sensing

Clofarabine in the treatment of newly diagnosed acute myeloid leukemia in older adults

P688: ASC2ESCALATE: A US PHASE 2, OPEN‐LABEL, SINGLE‐ARM, DOSE‐ESCALATION STUDY OF ASCIMINIB MONOTHERAPY IN 2ND‐LINE (2L) TREATMENT OF PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML‐CP)

Electrochemical behavior of oxazoline‐based plasma polymers for biosensing applications

Pilot-scale microfluidic solvent extraction of high-value metals

Incremental Healthcare Resource Utilization and Costs Associated with Non-Optimal Treatment in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Tyrosine Kinase Inhibitors (TKI) in Early Lines of Therapy in the United States (US)

Treatment Patterns and Modifications of Tyrosine Kinase Inhibitors (TKI) Therapy in Early Lines in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Real-World Analysis from a Large Commercial Claims Database in the United States (US)

Outside Front Cover: Plasma Process. Polym. 8/2023

Facile and green fabrication of efficient Au nanoparticles catalysts using plant extract via a mesoporous silica-assisted strategy

Treatment of Acute Promyelocytic Leukemia During Pregnancy

HSR24-147: Non-Optimal Treatment in Early-Line Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated With Tyrosine Kinase Inhibitors (TKI): A Claims Data Analysis

HSR24-139: Patient-Reported Outcome Measures Used in Patients With Chronic Phase-Chronic Myeloid Leukemia: A Systematic Review of the Literature

CML-205 Non-Optimal Treatment in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated With Tyrosine Kinase Inhibitors (TKI) in the United States: A Claims Data Analysis

Non-Optimal Treatment in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated With Tyrosine Kinase Inhibitors (TKI) in the United States: A Claims Data Analysis

ASC2ESCALATE: A US Phase 2, Open-Label, Single-Arm, Dose-Escalation Study of Asciminib (ASC) Monotherapy in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) As Second-Line (2L) and First-Line (1L) Treatment

Solid organ transplant patients: are there opportunities for antimicrobial stewardship?

ASC2ESCALATE: A US phase 2, single-arm, dose-escalation study of asciminib monotherapy in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with 1 prior tyrosine kinase inhibitor (TKI)

CML-068 Quantifying the Financial Impact of Treatment Intolerance in Chronic Myeloid Leukemia on Oncology Clinical Practices: A Mixed-Methods Study

Quantifying the Financial Impact of Treatment Intolerance in Chronic Myeloid Leukemia on Oncology Clinical Practices: A Mixed-Methods Study

CML-619 Adverse Events (AEs) Among Patients With Chronic Myeloid Leukemia (CML) Receiving Tyrosine Kinase Inhibitors and Subsequent Treatment Adjustment: A Large US Commercial Claims Database Analysis

Adverse Events (AEs) Among Patients With Chronic Myeloid Leukemia (CML) Receiving Tyrosine Kinase Inhibitors and Subsequent Treatment Adjustment: A Large US Commercial Claims Database Analysis

Continuous monitoring of EDTA extractable iron from mineral slurries using a microfluidic chip

The ever-evolving landscape of candidaemia in patients with acute leukaemia: non-susceptibility to caspofungin and multidrug resistance are associated with increased mortality

POSTER: CML-573 ASC2ESCALATE: A US, Phase II Open-Label, Single-Arm, Dose-Escalation Study of Asciminib Monotherapy in Second-Line (2L) and First-Line (1L) Treatment of Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Suchergebnisse filtern